Legend Biotech

Sr. Scientist of Immunology

Franklin Township, New Jersey, United States

Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, HealthcareIndustries

Requirements

The ideal candidate should possess a Ph.D. in immunology, oncology, or a related field, along with 3-5 years of experience in cell therapy, immunology, self-replicating virology, or autoimmune disease. Extensive knowledge of in vivo CAR-T and deep understanding of AID is required, alongside experience with cellular and immune cell-based analytics, assay development including multi-parameter flow-cytometry, and immunogenicity assays. Experience with lentivirus engineering, packaging, and characterization assays, as well as in vivo tissue/cell-specific gene delivery in animal models, is considered a plus, and genome editing experience is also beneficial.

Responsibilities

As a Senior Scientist of Immunology, the candidate will isolate immune cells, activate and expand them using flow cytometry, perform functional assays such as cytotoxicity and cytokine secretion, engineer virus genomes, package and characterize engineered virus particles, develop and optimize immunoassays to detect host immune response, conduct functional analysis of transduced cells, deliver experiment results meeting timelines, prepare reports and presentations, maintain laboratory documentation, ensure compliance with GLP and EHS protocols, and present results in team meetings.

Skills

flow cytometry
cytotoxicity
cytokine secretion
virus genome engineering
molecular assays
VCN analysis
immunoassays
CAR-T cells

Legend Biotech

Develops and commercializes cell therapies

About Legend Biotech

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates in the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's cells to combat cancer. Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments.

Key Metrics

Franklin Township, New JerseyHeadquarters
2014Year Founded
$146.4MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Paid Sick Leave
Paid Holidays
Remote Work Options

Risks

Increased competition from Amgen's Imdelltra may impact CAR-T therapy focus.
Collaboration with Multiply Labs may face technological challenges, delaying production timelines.
Financial strain from new R&D facility could affect operational focus if advancements lag.

Differentiation

Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
The company is technology agnostic, exploring multiple platforms for effective cancer treatments.
Legend Biotech's CARVYKTI® is the first BCMA-targeted CAR-T therapy approved for second-line use.

Upsides

Recent FDA and European approvals for CARVYKTI® expand its market reach in multiple myeloma.
New R&D facility in Philadelphia boosts innovation in next-generation cell therapies.
Alan Bash's appointment could accelerate CARVYKTI®'s growth and market penetration.

Land your dream remote job 3x faster with AI